{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:39:56Z","timestamp":1788349196985,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.psychres.2019.112606","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T19:21:57Z","timestamp":1570648917000},"page":"112606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Cardio-metabolic risk in individuals prescribed long-acting injectable antipsychotic medication"],"prefix":"10.1016","volume":"281","author":[{"given":"Rachel","family":"Morell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Poole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamish","family":"Fibbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Rossimel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gerrard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Teasdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip B.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Lappin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.psychres.2019.112606_bib0001","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.psychres.2019.112606_bib0002","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","article-title":"Metabolic syndrome\u2013a new world-wide definition. a consensus statement from the international diabetes federation","volume":"23","author":"Alberti","year":"2006","journal-title":"Diabetic Medicine"},{"issue":"2","key":"10.1016\/j.psychres.2019.112606_bib0003","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","year":"2004","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.psychres.2019.112606_bib0004","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/1039856217737899","article-title":"Compliance of metabolic monitoring at rehabilitation facilities","volume":"26","author":"Benson","year":"2018","journal-title":"Australasian Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2019.112606_bib0005","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.diabres.2007.02.002","article-title":"The metabolic syndrome in australia: prevalence using four definitions","volume":"77","author":"Cameron","year":"2007","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"4","key":"10.1016\/j.psychres.2019.112606_bib0006","doi-asserted-by":"crossref","first-page":"197","DOI":"10.5694\/j.1326-5377.2010.tb03478.x","article-title":"AUSDRISK: an australian type 2 diabetes risk assessment tool based on demographic, lifestyle and simple anthropometric measures","volume":"192","author":"Chen","year":"2010","journal-title":"Medicine Journal of Australia"},{"issue":"9","key":"10.1016\/j.psychres.2019.112606_bib0007","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1177\/0004867412449876","article-title":"Tobacco smoking among people living with a psychotic illness: the second australian survey of psychosis","volume":"46","author":"Cooper","year":"2012","journal-title":"Australian & New Zealand Journal of Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2019.112606_bib0008","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/schbul\/sbn018","article-title":"Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials","volume":"35","author":"Correll","year":"2008","journal-title":"Schizophr Bull"},{"issue":"2","key":"10.1016\/j.psychres.2019.112606_bib0009","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/wps.20420","article-title":"Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large\u2010scale meta\u2010analysis of 3,211,768 patients and 113,383,368 controls","volume":"16","author":"Correll","year":"2017","journal-title":"World Psychiatry"},{"issue":"8","key":"10.1016\/j.psychres.2019.112606_bib0010","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1249\/01.MSS.0000078924.61453.FB","article-title":"International physical activity questionnaire: 12-country reliability and validity","volume":"35","author":"Craig","year":"2003","journal-title":"Medicine & Science in Sports & Exercise"},{"issue":"3","key":"10.1016\/j.psychres.2019.112606_bib0011","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1751-7893.2011.00315.x","article-title":"The heart of the matter: cardiometabolic care in youth with psychosis","volume":"6","author":"Curtis","year":"2012","journal-title":"Early Interv Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2019.112606_bib0012","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/eip.12230","article-title":"Evaluating an individualized lifestyle and life skills intervention to prevent antipsychotic\u2010induced weight gain in first\u2010episode psychosis","volume":"10","author":"Curtis","year":"2016","journal-title":"Early Interv Psychiatry"},{"issue":"683","key":"10.1016\/j.psychres.2019.112606_bib0013","article-title":"y-QUIT: smoking prevalence, engagement, and effectiveness of an individualized smoking cessation intervention in youth with severe mental illness","volume":"9","author":"Curtis","year":"2018","journal-title":"Front Psychiatry"},{"issue":"17","key":"10.1016\/j.psychres.2019.112606_bib0014","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1214530","article-title":"A behavioral weight-loss intervention in persons with serious mental illness","volume":"368","author":"Daumit","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.psychres.2019.112606_bib0015","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/j.2051-5545.2011.tb00036.x","article-title":"Physical illness in patients with severe mental disorders. II. barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level.","volume":"10","author":"De Hert","year":"2011","journal-title":"World Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2019.112606_bib0016","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.eurpsy.2009.01.005","article-title":"Cardiovascular disease and diabetes in people with severe mental illness position statement from the european psychiatric association (EPA), supported by the european association for the study of diabetes (EASD) and the european society of cardiology (ESC)","volume":"24","author":"De Hert","year":"2009","journal-title":"European psychiatry"},{"key":"10.1016\/j.psychres.2019.112606_bib0017","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.schres.2018.07.033","article-title":"Changes in physical and psychiatric health after a multidisciplinary lifestyle enhancing treatment for inpatients with severe mental illness: the multi study i","volume":"204","author":"Deenik","year":"2018","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.psychres.2019.112606_bib0018","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/JCP.0000000000000140","article-title":"Comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized, open-label study in outpatients with schizophrenia","volume":"34","author":"Detke","year":"2014","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.psychres.2019.112606_bib0019","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/YIC.0b013e32834a5bf6","article-title":"The meteor study: frequency of metabolic disorders in patients with schizophrenia. focus on first and second generation and level of risk of antipsychotic drugs","volume":"26","author":"Falissard","year":"2011","journal-title":"Int Clin Psychopharmacol"},{"issue":"2\u20133","key":"10.1016\/j.psychres.2019.112606_bib0020","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2005.10.020","article-title":"Validation of a physical activity assessment tool for individuals with schizophrenia","volume":"82","author":"Faulkner","year":"2006","journal-title":"Schizophr. Res."},{"issue":"12","key":"10.1016\/j.psychres.2019.112606_bib0021","doi-asserted-by":"crossref","first-page":"e82606","DOI":"10.1371\/journal.pone.0082606","article-title":"Cardiometabolic risk indicators that distinguish adults with psychosis from the general population, by age and gender","volume":"8","author":"Foley","year":"2013","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.psychres.2019.112606_bib0022","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/YIC.0b013e32835b091f","article-title":"Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials","volume":"28","author":"Fusar-Poli","year":"2013","journal-title":"Int Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.psychres.2019.112606_bib0023","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0004867416641195","article-title":"Royal australian and new zealand college of psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders","volume":"50","author":"Galletly","year":"2016","journal-title":"Australian & New Zealand Journal of Psychiatry"},{"issue":"8","key":"10.1016\/j.psychres.2019.112606_bib0024","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/0004867412453089","article-title":"Cardiometabolic risk factors in people with psychotic disorders: the second australian national survey of psychosis","volume":"46","author":"Galletly","year":"2012","journal-title":"Aust N Z J Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2019.112606_bib0025","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17m12007","article-title":"Metabolic syndrome and illness severity predict relapse at 1-Year follow-up in schizophrenia: the face-sz cohort","volume":"79","author":"Godin","year":"2018","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"10.1016\/j.psychres.2019.112606_bib0026","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/j.1360-0443.1991.tb01879.x","article-title":"The fagerstr\u00f6m test for nicotine dependence: a revision of the fagerstrom tolerance questionnaire","volume":"86","author":"Heatherton","year":"1991","journal-title":"Br J Addict"},{"key":"10.1016\/j.psychres.2019.112606_bib0027","series-title":"SPSS","year":"2016"},{"issue":"1","key":"10.1016\/j.psychres.2019.112606_bib0028","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s12888-018-1848-y","article-title":"Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews","volume":"18","author":"Ijaz","year":"2018","journal-title":"BMC Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.psychres.2019.112606_bib0029","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.schres.2014.12.013","article-title":"Efficacy and safety of aripiprazole once-monthly in asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole","volume":"161","author":"Ishigooka","year":"2015","journal-title":"Schizophr. Res."},{"issue":"21","key":"10.1016\/j.psychres.2019.112606_bib0030","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1001\/jama.288.21.2709","article-title":"The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men","volume":"288","author":"Lakka","year":"2002","journal-title":"Journal of American Medical Association"},{"key":"10.1016\/j.psychres.2019.112606_bib0031","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.schres.2018.02.035","article-title":"Cardio-metabolic risk and its management in a cohort of clozapine-treated outpatients","volume":"199","author":"Lappin","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2019.112606_bib0032","doi-asserted-by":"crossref","first-page":"f2539","DOI":"10.1136\/bmj.f2539","article-title":"The gap in life expectancy from preventable physical illness in psychiatric patients in western australia: retrospective analysis of population based registers","volume":"346","author":"Lawrence","year":"2013","journal-title":"Br Med J"},{"issue":"4_suppl","key":"10.1016\/j.psychres.2019.112606_bib0033","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/1359786810382058","article-title":"Review: inequalities in healthcare provision for people with severe mental illness","volume":"24","author":"Lawrence","year":"2010","journal-title":"Journal of Psychopharmacology"},{"issue":"2 SUPPL.","key":"10.1016\/j.psychres.2019.112606_bib0034","article-title":"Practice guideline for the treatment of patients with schizophrenia","volume":"161","author":"Lehman","year":"2004","journal-title":"American Journal of Psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2019.112606_bib0035","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1192\/bjp.bp.105.015933","article-title":"Delivering medical care for patients with serious mental illness or promoting a collaborative model of recovery?","volume":"188","author":"Lester","year":"2006","journal-title":"The British Journal of Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.psychres.2019.112606_bib0036","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2010.11.020","article-title":"Oral versus depot antipsychotic drugs for schizophrenia\u2014a critical systematic review and meta-analysis of randomised long-term trials","volume":"127","author":"Leucht","year":"2011","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.psychres.2019.112606_bib0037","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1600-0447.2007.01095.x","article-title":"Physical illness and schizophrenia: a review of the literature","volume":"116","author":"Leucht","year":"2007","journal-title":"Acta Psychiatr Scand"},{"issue":"suppl_1","key":"10.1016\/j.psychres.2019.112606_bib0038","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","article-title":"Dose equivalents for antipsychotic drugs: the ddd method","volume":"42","author":"Leucht","year":"2016","journal-title":"Schizophr Bull"},{"issue":"12","key":"10.1016\/j.psychres.2019.112606_bib0039","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.2105\/AJPH.2009.188136","article-title":"Smoking characteristics of adults with selected lifetime mental illnesses: results from the 2007 national health interview survey","volume":"100","author":"McClave","year":"2010","journal-title":"Am J Public Health"},{"issue":"6","key":"10.1016\/j.psychres.2019.112606_bib0040","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hup.1225","article-title":"Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long\u2010acting injection versus oral olanzapine","volume":"26","author":"McDonnell","year":"2011","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"issue":"1","key":"10.1016\/j.psychres.2019.112606_bib0041","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","article-title":"Classification of typical and atypical antipsychotic drugs on the basis of dopamine d-1, d-2 and serotonin2 pKi values","volume":"251","author":"Meltzer","year":"1989","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"8","key":"10.1016\/j.psychres.2019.112606_bib0042","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1177\/0004867412449877","article-title":"People living with psychotic illness in 2010: the second australian national survey of psychosis","volume":"46","author":"Morgan","year":"2012","journal-title":"Australian & New Zealand Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2019.112606_bib0043","unstructured":"National Institute for Health and Care Excellence, 2014. Psychosis and schizophrenia in adults: prevention and management - Clinical guideline [CG178], London, UK."},{"issue":"Suppl4","key":"10.1016\/j.psychres.2019.112606_bib0044","first-page":"8","article-title":"Antipsychotic medications: metabolic and cardiovascular risk","volume":"68","author":"Newcomer","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.psychres.2019.112606_bib0045","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.psychres.2019.112606_bib0046","first-page":"379","article-title":"Metabolic syndrome and cardiovascular risk in people treated with long-acting injectable antipsychotics. endocrine, metabolic & immune disorders-drug targets (Formerly current drug targets-immune","volume":"18","author":"Sanchez-Martinez","year":"2018","journal-title":"Endocrine & Metabolic Disorders)"},{"key":"10.1016\/j.psychres.2019.112606_bib0047","series-title":"Update (with Acknowledgement to the Late Helen Lester For Her Contribution to the Original 2012 version) Positive Cardiometabolic Health Resource: an Intervention Framework For Patients With Psychosis and schizophrenia. 2014 Update","author":"Shiers","year":"2014"},{"issue":"3","key":"10.1016\/j.psychres.2019.112606_bib0048","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2174\/15748847113089990051","article-title":"The pharmacokinetics of long-acting antipsychotic medications","volume":"9","author":"Spanarello","year":"2014","journal-title":"Curr Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.psychres.2019.112606_bib0049","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1192\/bjp.bp.115.177139","article-title":"Solving a weighty problem: systematic review and meta-analysis of nutrition interventions in severe mental illness","volume":"210","author":"Teasdale","year":"2017","journal-title":"The British Journal of Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2019.112606_bib0050","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/wps.20252","article-title":"Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis","volume":"14","author":"Vancampfort","year":"2015","journal-title":"World Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2019.112606_bib0051","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/wps.20252","article-title":"Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta\u2010analysis","volume":"14","author":"Vancampfort","year":"2015","journal-title":"World Psychiatry"},{"key":"10.1016\/j.psychres.2019.112606_bib0052","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3389\/fpsyt.2018.00744","article-title":"Metabolic syndrome in psychotic disorder patients treated with oral and long-acting injected antipsychotics","volume":"9","author":"Ventriglio","year":"2018","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.psychres.2019.112606_bib0053","series-title":"Physical status: The use of and Interpretation of anthropometry, Report of a WHO Expert Committee","year":"1995"},{"key":"10.1016\/j.psychres.2019.112606_bib0054","series-title":"Global Recommendations On Physical Activity For Health","year":"2010"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178119315677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178119315677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T05:40:23Z","timestamp":1759038023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178119315677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":54,"alternative-id":["S0165178119315677"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2019.112606","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardio-metabolic risk in individuals prescribed long-acting injectable antipsychotic medication","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2019.112606","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112606"}}